Altamira Therapeutics Ltd.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Altamira Therapeutics Ltd. generated cash of -$11,511,064, which is less than the previous year. Cash used in financing activities reached the amount of $10,621,615 last year. Net change in cash is therefore $602,014.
Cash Flow
| 2014 | -19.31M | -1.18M | 49.60M |
|---|---|---|---|
| 2015 | -28.72M | -43.35K | 20.91M |
| 2016 | -29.45M | -176.77K | 11.43M |
| 2017 | -24.27M | -99.39K | 8.22M |
| 2018 | -13.23M | -1.82M | 5.73M |
| 2019 | -8.39M | -3.00M | 7.37M |
| 2020 | -4.84M | -2.31M | 16.96M |
| 2021 | -13.67M | -3.50M | 6.61M |
| 2022 | -8.68M | -2.14M | 9.83M |
| 2023 | -11.51M | 1.44M | 10.62M |
EARS Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 15.39K | 984.19K | 11.25M | 1.38M | 5.39M | 14.97M | 32.44M | 50.23M | 56.93M | 23.86M |
Operating activities | ||||||||||
Net income | -3.86M | -26.52M | -17.39M | -8.20M | -6.63M | -11.49M | -24.40M | -30.66M | -29.70M | -18.18M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 119.30K | 118.88K | 76.35K | 20.03K | 30.82K | 72.71K | 122.78K | 97.6K | 92.77K | 73.98K |
Stock-based compensation expense | 0 | 342.79K | 1.20M | 368.79K | 226.60K | 0 | 354.85K | 290.78K | 311.67K | 270.74K |
| Deferred income tax benefit | 0 | 342.79K | 1.20M | 368.79K | 226.60K | 0 | 354.85K | 290.78K | 311.67K | 270.74K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 14.06K | -103.60K | -340.11K | 254.43K | -18.92K | -18.39K | 93.32K | 277.48K | -146.24K | -17.63K |
Inventories | -319.82K | 827.57K | -839.22K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -14.06K | 103.60K | 340.11K | 0 | 0 | 0 | -637.17K | 632.47K | -2.02M | 0 |
Cash generated by operating activities | -11.51M | -8.68M | -13.67M | -4.84M | -8.39M | -13.23M | -24.27M | -29.45M | -28.72M | -19.31M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | -179.10K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -2.14M | -3.32M | -2.31M | -3.01M | -1.89M | -152.96K | -244.32K | -79.92K | -1.23M |
Acquisitions Net | 1.43M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 1.44M | -2.14M | -3.50M | -2.31M | -3.00M | -1.82M | -99.39K | -176.77K | -43.35K | -1.18M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 9.79M | 17.44M | 13.03M | 0 | 21.07M | 50.03M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 1.04M | 5.92M | -68.7K | -1.52M | -1.46M | -9.27M | -2.08M | -11.98M | 0 | 0 |
Cash used in financing activities | 10.62M | 9.83M | 6.61M | 16.96M | 7.37M | 5.73M | 8.22M | 11.43M | 20.91M | 49.60M |
Net Change In Cash | 602.01K | -968.79K | -10.27M | 9.87M | -4.00M | -9.58M | -17.46M | -17.79M | -6.69M | 33.06M |
Cash at end of period | 617.40K | 15.39K | 984.19K | 11.25M | 1.38M | 5.39M | 14.97M | 32.44M | 50.23M | 56.93M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |